
==== Front
J Dev Biol
J Dev Biol
jdb
Journal of Developmental Biology
2221-3759
MDPI

10.3390/jdb12030024
jdb-12-00024
Review
Roles of the NR2F Family in the Development, Disease, and Cancer of the Lung
Yang Jiaxin 12
Sun Wenjing 2
https://orcid.org/0000-0001-6394-2773
Cui Guizhong 12*
Conway Simon J. Academic Editor
1 Department of Basic Research, Guangzhou National Laboratory, Guangzhou 510005, China; yang_jiaxin@gzlab.ac.cn
2 School of Basic Medical Sciences, Guangzhou Medical University, Guangzhou 511436, China; 2023210098@stu.gzhmu.edu.cn
* Correspondence: cui_guizhong@gzlab.ac.cn
10 9 2024
9 2024
12 3 2421 4 2024
24 8 2024
30 8 2024
© 2024 by the authors.
2024
https://creativecommons.org/licenses/by/4.0/ Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
The NR2F family, including NR2F1, NR2F2, and NR2F6, belongs to the nuclear receptor superfamily. NR2F family members function as transcription factors and play essential roles in the development of multiple organs or tissues in mammals, including the central nervous system, veins and arteries, kidneys, uterus, and vasculature. In the central nervous system, NR2F1/2 coordinate with each other to regulate the development of specific brain subregions or cell types. In addition, NR2F family members are associated with various cancers, such as prostate cancer, breast cancer, and esophageal cancer. Nonetheless, the roles of the NR2F family in the development and diseases of the lung have not been systematically summarized. In this review, we mainly focus on the lung, including recent findings regarding the roles of the NR2F family in development, physiological function, and cancer.

NR2F family
lung
carcinogenesis
nuclear receptors
National Natural Science Foundation of China32100483 Major Project of Guangzhou National LaboratoryGZNL2023A02007 GZNL2023A03005 This research was funded by the National Natural Science Foundation of China (32100483) and the Major Project of Guangzhou National Laboratory (GZNL2023A02007, GZNL2023A03005).
==== Body
pmc1. Introduction

Nuclear receptors (NRs), a family of evolutionarily conserved proteins, are ligand-activated transcription factors that participate in the regulation of both physiological and pathological processes [1]. In humans, 48 NRs have been identified, including receptors for steroid hormones, thyroid hormones, cholesterol metabolites, and lipophilic vitamins. NRs are categorized into seven classes: Class 0: miscellaneous; Class I: thyroid hormone receptor-like; Class II: retinoid X receptor-like; Class III: estrogen receptor-like; Class IV: nerve growth factor IB-like; Class V: steroidogenic factor-like; Class VI: germ cell nuclear factor-like [2]. NRs share common structural characteristics, including a transactivation region, a central DNA-binding domain, a region responsible for nuclear localization, and a ligand-binding domain. They function as transcription factors and regulate the expression of genes involved in metabolism, fertility, immunity, angiogenesis and other biological processes [3]. The Nuclear Receptor Subfamily 2 Group F (NR2F) family belongs to Class II of the nuclear receptor superfamily. Due to the lack of identified endogenous ligands, NR2F family members are also known as orphan nuclear receptors.

In humans, the main members of the NR2F family include NR2F1, NR2F2, and NR2F6. NR2F1 and NR2F2 are also named COUP-TFI (Chicken Ovalbumin Upstream Promoter Transcription Factor I) and COUP-TFII (Chicken Ovalbumin Upstream Promoter Transcription Factor II), respectively [4,5,6]. NR2F1 and NR2F2 contain two highly conserved domains, the DNA-binding domain and the ligand-binding domain. NR2F1 and NR2F2 are highly conserved across vertebrate species (in many cases, the conserved subdomains exceed 95% homology) [5]. In general, the NR2F family members exert their functions through two major mechanisms. One is direct regulation by binding to DNA elements, including direct repeat-1, which directly suppresses or activates the expression of target genes. The other mechanism is indirect regulation by interacting with transcription factors such as SP1 to activate the expression of target genes [7,8,9]. NR2F family members perform regulatory functions by forming homodimers or heterodimers. In addition to self-dimerization, NR2F family members also competitively bind with other nuclear receptors, such as retinoic X receptors (RXRs), to inhibit the function of other nuclear receptors [10]. Consequently, several nuclear receptors, such as thyroid hormone receptors (TRs) and retinoic acid receptors (RARs), have been shown to have crosstalk with NR2F family members [10,11].

Previous studies have shown that the NR2F family plays pivotal roles in mammalian embryonic development. For example, in the central nervous system (CNS), Nr2f1 orchestrates the regionalization of neocortex [12]; meanwhile, both Nr2f1 and Nr2f2 are involved in the development of cortical interneurons and the generation of the dorsal–ventral axis of the hippocampus [13,14,15]. Moreover, several studies have demonstrated that mutations in NR2F1 lead to Bosch–Boonstra–Schaaf optic atrophy syndrome (BBSOAS), which has various symptoms, such as optic atrophy, autism, mental retardation and epilepsy [16,17,18]. It is noteworthy that Nr2f1 and Nr2f2 often have a complementary effect on neuronal development. Additionally, Nr2f2 regulates vasculogenesis in the heart and spinal cord, as well as the development of the kidney, stomach, and diaphragm [19,20,21]. Nr2f6 is involved in adipocyte differentiation, and it is also considered an essential factor in immune checkpoint regulation to manipulate the development and physiological functions of immune cells [22,23].

Numerous reports have suggested that the NR2F family members are highly involved in cancer, including breast cancer, prostate cancer, and liver cancer [24,25,26,27,28]. Dysregulated long noncoding RNAs associated with the NR2F family have been identified in cancers. For example, NR2F1 interacted with NR2F1-AS1 to activate the Sonic Hedgehog signaling pathway and promote the progression of esophageal squamous cell carcinoma [29]. The functions of the NR2F family in CNS development have been reviewed [17,30]. Nevertheless, the roles of the NR2F family in cancer occurrence and progression still lack in-depth studies and systematic summaries. In this review, we summarize the current understanding of the NR2F family in lung development and pathological conditions, proposing an updated and critical view of the various functions of NRs.

2. NR2F Family in Lung Development and Non-Cancerous Diseases

In mice, lung development begins at E9.0. By E9.5, lung progenitors form the trachea and buds, progressing through stages to generate functional lungs [31] (Figure 1a). Multiple genes regulate lung development. For instance, Fgf10 regulates early branching morphogenesis [32,33,34]. Sox2 and Sox9/Id2 dominate the proximal–distal axis patterning. Proximal cells with high Sox2 expression develop into neuroendocrine cells and non-neuroendocrine cells, while distal cells with high Sox9/Id2 expression give rise to type I and type II alveolar cells. Alveolar cells are responsible for gas exchange, morphology maintenance, and surfactant secretion [31,35,36]. Abnormalities in terms of lung development can cause diseases like bronchopulmonary dysplasia [37].

Previous studies have demonstrated that NR2F2 is widely expressed in the developing lung [38]. With advancements in single-cell RNA sequencing and the stem cell-derived organoid system, NR2F1 has been shown to be expressed in the foregut and developing lung epithelium and mesenchyme [39]. Both blood vessels and lymph vessels are essential components of the lung mesenchyme. Recent studies suggest that the NR2F family may play critical roles in lung angiogenesis and lymphangiogenesis. NR2F1 and NR2F2 have been identified as lymphatic marker genes, with NR2F2 specifically marking venous endothelial cells [40] (Figure 1b). Additionally, NR2F1 has been suggested in a BioRx preprint to be one of the genes involved in the core organ-size regulation program, displaying a unique expression pattern in the developing swine lung epithelium and mesenchyme [41]. In the lung epithelium, the expression of NR2F1 is restricted to the initial stages of lung development, whereas it is almost absent in later stages. In contrast, in the lung mesenchyme, NR2F1 is continuously expressed throughout development. Furthermore, a function of Nr2f1 in the growth and differentiation of ciliated bronchial epithelium was uncovered in a study evaluating the role of Pten overexpression in lung cancer [42]. Pten overexpression blocked this function of Nr2f1. These authors also found that Nr2f1 upregulated other ciliogenesis-related genes, including Mucin5a, DNAI2, and DNAI3 (Figure 1c). Despite some progress in understanding the role of the NR2F family in lung development, the regulatory mechanisms remain largely unexplored. Nonetheless, the association of the NR2F family with various lung-related diseases underscores its significant functions in the lung.

Congenital diaphragmatic hernia (CDH) is a severe lung-related developmental disease with an incidence rate of approximately 1/3000 and a mortality rate exceeding 30%. Several studies suggest that NR2F2 deficiency induces CDH [21,43]. Moreover, pulmonary fibrosis is a progressive lung disease characterized by fibrosis and scar formation in the distal lungs. Idiopathic pulmonary fibrosis (IPF) is the most common form of pulmonary fibrosis without effective treatment available to date. Several studies demonstrated that Nr2f2 can affect IPF by influencing downstream genes such as Col1a1 and Fn1, inhibiting the activation of fibroblasts and the production of extracellular matrix, and enhancing the dissolution of fibrosis [44,45]. Lymphangioleiomyomatosis (LAM), another lung disease, is characterized by abnormal proliferation of smooth muscle, which leads to the obstruction of pulmonary bronchioles and lymphatics, as well as lung function impairment, including pneumothorax. Recent research indicates the potential roles of NR2F2 in the progression of LAM due to its overexpression in tumor tissues [46].

3. NR2F Family in Primary Lung Cancer

Lung cancer is the leading cause of cancer-related deaths worldwide. Lung cancer can be categorized into small-cell lung cancer and non-small-cell lung cancer (NSCLC). Small-cell lung cancer, characterized by rapid growth and high metastatic potential, is less common but predominantly found in smokers, with most patients exhibiting TP53 mutations [47,48,49]. NSCLC, which accounts for over 85% of all lung cancer cases, can be further classified into lung squamous cell carcinoma (LUSC), lung adenocarcinoma (LUAD), and large cell carcinoma. LUSC and LUAD have been prevalent and extensively studied [47]. LUSC originates mainly from the internal epithelial cells of the bronchi or bronchioles, and it is characterized by a squamous cell morphology, keratinization, and the presence of intercellular bridges [50]. LUAD arises from glandular cells with secretory functions in the lungs and exhibits diverse morphological features, and it can be identified by NKX2.1 expression or Napsin-A staining [47].

Studies on LUAD have found that the overexpression of NR2F1 can enhance the migration and invasion of tumor cells, probably through NR2F1-AS1, which is upregulated by NR2F1 and ZEB1 [51]. Intriguingly, the overexpression of NR2F2 in lung tumor cells also enhances their invasion and migration capabilities by in vitro modeling [52]. Furthermore, NR2F2 is regulated by the Wnt signaling pathway to activate the expression of GPX4, which could induce high glutathione (GSH) consumption to inhibit ferroptosis and lead to the drug resistance of lung cancer cells that metastasize to the brain [53]. Additionally, NR2F6 expression is significantly upregulated in LUAD tissue [54], and the single nucleotide variation of NR2F6 is strongly related to the survival rate of patients in the early stage of NSCLC [55]. These results from lung and other tissue cancer studies suggest that NR2F6 plays important roles in immunity, metabolism, and the reaction of T cell responses to inflammatory cytokines, such as IL2 and TNFβ, which mediate anti-cancer immune reactions [23,56] (Table 1).

4. NR2F Family in Metastatic Lung Cancer

Most cancer-related deaths result not from the primary tumor itself but from metastatic dissemination [60]. In the later stages of cancer, primary tumor cells undergo transformation, then travel to distant sites, and re-establish tumor clones. Almost any cancer can spread to the lungs since all blood must pass through the lungs during oxygenation and any circulating tumor cell could be filtered out in its rich capillary network. Many cancer patients in advanced stages are often discovered to have lung lesions, particularly in patients with breast and colon cancer, which are highly prone to lung metastasis. The late-stage metastasis of tumor cells is an important factor contributing to the challenge of the treatment and the high mortality rate. The process of tumor cell metastasis to the lungs involves several stages, including tumor cells detaching from the primary tumor tissue, infiltrating surrounding tissues, invading the blood or lymphatic vessels, entering the lungs through the bloodstream and lymphatics, extravasating from the vessels, colonizing in lung tissue, initiating growth, and eventually forming metastatic lung cancer [61,62].

During tumor cell metastasis, several crucial biological processes unfold, including reshaping of the tumor microenvironment (TME), transformation of the tumor cell status, and the dormancy and activation of tumor cells [61,62,63,64]. Reshaping the TME primarily involves the activation of inflammatory responses, increased angiogenesis, and immune suppression [63]. The transformation of the tumor cell status includes the transition of tumor cells from an epithelial cell state to a mesenchymal cell state, known as epithelial–mesenchymal transition (EMT), during the initial stages of metastasis, facilitating migration and invasion. Subsequently, upon reaching distant organs via the bloodstream, tumor cells may undergo mesenchymal–epithelial transition (MET), reverting to an epithelial state to support rapid proliferation [61,62,63]. Upon initial arrival in the lungs, tumor cells often enter a period of dormancy before being reactivated, which is possibly related to the establishment of a new niche of tumor cells in the lungs, and it is also a significant reason why many cancer patients experience recurrence after undergoing curative treatment [61,64].

Studies using animal models of metastatic lung cancer indicate that elevated NR2F1 expression in tumor cells can induce dormancy in lung tissues by co-regulating with SMAD4 and TGFβ, causing tumor cells to exit the cell cycle [65]. Similarly, NR2F1-AS1 upregulates NR2F1 expression to suppress ΔNp63 expression and prevent the MET process in tumor cells, leading to reduced proliferation of breast cancer cells that have metastasized to the lungs [66].

In both human tissues and cellular models, NR2F1 suppresses the metastasis of salivary adenoid cystic carcinoma (SACC) tumor cells to the lungs by upregulating the CXCL12/CXCR4 pathway [67]. Nr2f2 modulates the metastasis of breast tumor cells to the lungs by activating the expression of Ang1, thereby promoting tumor angiogenesis, facilitating the provision of nutrients and oxygen to support tumor cell metastasis to the lungs [24]. Additionally, reports on gastric cancer with lung metastases have discovered that Fbxo21 inhibits EMT by suppressing Nr2f2 in both in vivo tissues and in vitro cell lines [68]. These findings underscore the involvement of the NR2F family in the metastatic processes of various tumor cells in relation to the lungs, which could indicate its significance in the progression of metastatic lung cancer (Table 2).

5. Other Members of the Nuclear Receptor Superfamily Associated with the NR2F Family and Lung Cancer

In addition to the NR2F family, there are more than 40 members of the nuclear receptor superfamily [70], many of which play important roles in organ development and homeostasis, including the lungs. These nuclear receptors actively regulate various cellular functions; in addition, the expression levels of many nuclear receptors, such as progesterone receptor (PR), have been identified as prognostic factors for lung cancer patients [71,72]. The NR2F family members either interact with other nuclear receptors, such as RXRs, to form heterodimers or compete with other nuclear receptors for the binding sites of target genes to mutually regulate their functions [10]. Therefore, summarizing the roles of other nuclear receptors in lung cancer can provide further insights into their interaction mechanisms with the NR2F family (Figure 2).

5.1. Estrogen Receptors (ERs)

ERs belong to Cass III of the nuclear receptor superfamily and serve as receptors for the steroid hormone estrogen. ERs, including two subtypes ERα and ERβ, play essential roles in normal cell growth, differentiation, and survival [70]. Several reports have revealed a close association between ERs and NR2F2 expression. NR2F2 is highly expressed in ER-positive breast cancer cell lines but is poorly expressed in ER-negative breast cancer cell lines [73]. Additionally, Nr2f1 can also modulate the activity of ERs [74]. Studies in non-small-cell lung cancer have shown the dynamic expression of ERs, indicating that ERs could potentially have diverse functions in the genesis and progression of lung cancer [75,76,77,78]. Treatment with ER agonists have been found to increase the proliferation of lung tumor cells in animal models, while ER antagonists inhibit cell growth through IL-6 [79].

5.2. Progesterone Receptor (PR)

Similar to ERs, PR belongs to Class III of the nuclear receptor superfamily and is a receptor for progesterone. PR has two isoforms, PR-A and PR-B, which form homodimers or heterodimers to bind to the progesterone response elements (PREs) on DNA and to regulate the expression of target genes [80]. In breast cancer cell lines, PR and ERs collaborate to downregulate the transcription of NR2F1-AS1 [81]. During embryonic implantation, PR regulates the expression of NR2F2 by controlling Indian Hedgehog, which can activate NR2F2, then NR2F2 inhibits ERs in the uterine epithelium [82]. Several studies have shown a significant decrease of PR in lung cancer tissues [83], and similar results were observed in a mouse model with lung tumor cells transplanted [84], suggesting that PR could be a potential target for lung cancer treatment.

5.3. Retinoic Acid Receptors (RARs)

RARs belong to Class I of the nuclear receptor superfamily and act as receptors for retinoic acid. RARs, which can be classified into three subtypes, RARα (NR1B1), RARβ (NR1B2), and RARγ (NR1B3), regulate cell proliferation, differentiation, and death [70]. Previous studies indicated that the NR2F family members inhibit the target gene regulation of RARs [10]. Intriguingly, NR2F1/2 can be activated by RA signals [85]. In turn, NR2F2 induces the expression of RARβ through RA and RARα [86]. RARβ is considered a tumor suppressor in epithelial cells [87,88]. For example, the expression of RARβ was downregulated in lung tumor tissues, suggesting a potential tumor-suppressive role of RARβ [89,90,91]. Nevertheless, the upregulation of RARβ is also observed in lung cancer tissues [92]. Therefore, further investigation into the roles of RARs and their potential interactions with the NR2F family in lung cancer is warranted.

5.4. Retinoic X Receptors (RXRs)

RXRs belong to Class II of the nuclear receptor superfamily and serve as receptors for 9-cis-retinoic acid. RXRs are mainly divided into RXRα (NR2B1), RXRβ (NR2B2), and RXRγ (NR2B3), and RXRγ can further be subdivided into RXRγ1 and RXRγ2 [93]. RXRs can form heterodimers with several nuclear receptor families, including the NR2F family [10,94]. Studies have shown the downregulation of RXRs in lung cancer tissues [95]. Treatment with RXRs agonists, such as bexarotene, inhibits tumor angiogenesis, suppresses the proliferation and migration of lung tumor cells, and promotes tumor cell death through the PPARγ, PTEN, and mTOR pathways [96].

5.5. Peroxisome-Proliferator-Activated Receptors (PPARs)

PPARs belong to Class I of the nuclear receptor superfamily and are receptors for fatty acids. PPARs have three subtypes: PPARα, PPARβ, and PPARγ. They form heterodimers to bind onto the peroxisome proliferator response elements (PPREs) on target genes. PPARs are prominently expressed in adipocytes, and the Wnt/β-catenin signaling pathway can increase the expression of NR2F2 to inhibit PPARγ expression, leading to the suppression of adipogenesis [97]. In addition, a significant decrease of PPARγ expression was reported in lung cancer research [98]. Treatment with PPARγ ligands in adenocarcinoma cell lines inhibits cell proliferation, suggesting that PPARγ ligands hold promise as potential therapeutic agents [99].

5.6. Vitamin D Receptors (VDRs)

Vitamin D is synthesized by cells of the immune system and plays a critical role in anti-proliferative activities in cancer cells, such as breast, colon, and stomach tumor cells. VDRs are steroid hormone receptors that induce a cascade of cell signaling to maintain healthy Ca2+ levels, which serve to control several biological processes. The NR2F family may compete with VDRs to bind to elements of the VDRs, such as DR3, on their target genes to inhibit the activity of VDRs [10]. The expression levels of VDRs in lung cancer tissues are higher than those in non-cancerous tissues [100]. The expression of VDRs was also associated with improved survival in another lung cancer study [101], suggesting that the dysregulation of VDRs may interact with the NR2F family, leading to malignant transformation in the lungs.

5.7. Thyroid Hormone Receptors (TRs)

TRs belong to Class I of the nuclear receptor superfamily and act as receptors for thyroid hormone. TRs consist of two subtypes, TRα and TRβ, which are important regulators of many fundamental physiological processes, including development, growth, and metabolism. The NR2F family inhibits the activities of TRs on their target genes by competing for the TRs’ binding sites [10]. TRα is significantly higher expressed in LUSC than in LUAD, indicating that it may play a dominant role in LUSC [102]. Intriguingly, both types of lung cancer patients exhibit the loss of TRβ expression [103], demonstrating that TRs play diverse roles in different subtypes of lung cancer.

6. Discussion

The NR2F family not only plays a role in lung development but also contributes to various lung-related diseases, such as CDH, IPF, and lymphangioleiomyomatosis. Moreover, the NR2F family is essential for the progression of both primary lung cancer and metastatic lung cancer. In primary lung cancer, NR2F1 and NR2F2 influence the migration and invasion of tumor cells, while NR2F6 acts as an immune checkpoint factor to modulate immune processes. In metastatic lung cancer, NR2F1 mainly inhibits the transition of dormant tumor cells to a proliferative state in the lungs, while NR2F2 influences tumor cell metastasis to the lungs by affecting the tumor microenvironment, such as angiogenesis or EMT. NR2F1-AS1 is closely linked to NR2F1-related functions in the progress of lung cancer. Previous studies have provided some preliminary insights into the regulatory mechanisms of the NR2F family in lung cancer and other lung diseases; nonetheless, how the NR2F family participates in the regulation of the tumor microenvironment in lung cancer is still largely unclear. The roles of lung cancer-related genes, such as KRAS, EGFR, and ALK, have been systematically investigated in specific animal models of cancers [104]. However, previous studies on the NR2F family in the lungs have mostly been conducted using lung cancer cell lines or clinical tissue samples. The generation of specific lung cancer animal models for NR2F1, NR2F2, and NR2F6 will not only enhance the understanding of the molecular mechanisms of lung cancer but also improve the diagnosis and therapy for lung cancer associated with NR2F family dysregulation.

Previous studies have demonstrated that nuclear receptors are excellent targets for cancer therapy. Currently, drugs against nuclear receptors, such as ER and RXR, have been developed and used to treat various cancers, including breast cancer, with convincing efficacy [105]. The NR2F nuclear receptor subfamily, which interacts with various nuclear receptors, including RARs and RXRs, is a potential novel therapeutic target in cancer, especially in lung cancer.

Single-cell and spatial omics technologies are rapidly advancing and have been widely applied to research on development and disease, which enables precise identification of cellular heterogeneity and cell–cell communications. Spatial omics technology, which can simultaneously provide spatial location and omics information of tissues, makes it possible to uncover the interactions among cells in the tumor microenvironment [106]. Recently, spatial omics methods have been used to compare the difference between primary and metastatic tumor tissues in the brain metastasis of NSCLC. Changes in the immune-suppressive and fibrotic microenvironment were identified, and those changes aid the metastatic tumor cells in creating a suitable niche for rapid proliferation and progression in the brain [107].

In summary, the expression and functions of the NR2F family are closely associated with lung development and lung-related diseases. By establishing well-designed animal models targeting the NR2F family members in the lungs and combining the latest technologies, like spatial omics, a better understanding of the molecular and cellular mechanisms of the NR2F family in the development and diseases of the lung may be achieved, which will benefit the findings of novel diagnostic and therapeutic approaches for NR2F-related lung diseases, including lung cancer.

Acknowledgments

We thank Guangdun Peng for the discussions, Ke Tang for the helpful feedback on the manuscript, and the anonymous reviewers for the useful suggestions.

Author Contributions

J.Y. and G.C. conceptualized the subject, reviewed the literature, and wrote the draft manuscript. W.S. assisted in the manuscript’s preparation. G.C., J.Y. and W.S. designed the figures, and revised and finalized the manuscript. All authors have read and agreed to the published version of the manuscript.

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

Not applicable.

Conflicts of Interest

The authors declare no conflicts of interest.

Figure 1 Roles of the NR2F family in the lung development. (a) An illustration of lung development. (b) NR2F1/2 were identified as markers of angiogenesis and lymphangiogenesis in lung. (c) Up-regulation of Nr2f1 increases the number of lung bronchial epithelial ciliated cells through cilia-related genes such as DNAI2.

Figure 2 The effect of nuclear receptors in lung cancer. These seven nuclear receptors are all associated with the NR2F family, and the nuclear receptors near the left of the figure tend to have a positive effect in lung cancer, while the nuclear receptors near the right of the figure tend to have a negative effect, and the nuclear receptors near the middle of the figure have a debatable effect.

jdb-12-00024-t001_Table 1 Table 1 Primary lung diseases related to the NR2F family.

Disease Type	Genes	Functions	Models/Cell Lines/Tissues	Related Genes	Related Pathways	Reference	
Non-cancerous	CDH	Nr2f2↑	May rescue lung hypoplasia and enhance lung growth	Nitrofen rat model of CDH	Fog2 and Gata4	-	[57]	
Nr2f2↓	Formation of CDH	Nkx3-2Cre/+; Nr2f2flox/flox mouse model	Fog2	-	[21]	
NR2F2↓	Formation of CDH	15q deletion patients specimens	CHD2, RGMA and SIAT8B	-	[43]	
IPF	Nr2f2↑	Decreases fibrosis	Bleomycin-treated mice model	Fn1 and Col1a1	-	[44]	
LAM	NR2F2↑	Drives LAM pathogenesis	S-LAM patients specimens	MCTP2 and SPATA8	-	[46]	
Cancerous	NSCLC	NR2F1-AS1↓	Decrease NSCLC cell proliferation, migration, and invasion and promoted tumor cell apoptosis	NSCLC patients specimens; BEAS-2B, H522, H460, H1299, A549 and SK-MES-1 cell lines; nude mice	-	NR2F1-AS1/miR-493-5p/ITGB1 pathway	[58]	
NSCLC	NR2F1-AS1↑	Tumorigenic, promotes glycolysis and glutamine metabolism	NSCLC patients’ specimens; 16HBE, A549 and H522 cells	-	miR-363–3p/SOX4 axis	[59]	
LUAD	NR2F6↑	Promote proliferation, migration, invasion and enhances cell apoptosis	Lung adenocarcinoma patients specimens; A549, HCC827, HBE cells	miR-142-3p	-	[54]	
Lung Carcinoma	NR2F2↑	Promote cell invasion	A549, HeLa, NCI-H460, H661, H520, H441, MDAMB231 and H460SMcells	FAK(PTK2), MMP2, uPA and uPAR	-	[52]	
LUAD	NR2F1↑	Promote growth, migration, invasion, and tumorigenicity of lung adenocarcinoma cells	393P, 344SQ, 412P, 307P, 344LN, 344P, 393LN, 531LN1, 531LN2, 531LN3, 531P1, 531P2, 713P, A549 and HCC827 cells	ZEB1	ZEB1/NR2F1/NR2F1-AS1 axis	[51]	
LUAD	NR2F2↑	Induces platinum chemotherapeutic resistance in lung cancer brain metastasis	PC9, PC9-BrM1 and PC9-BrM3 cells; Nude mice	GSTM1 and GPX4	Wnt signaling pathway	[53]	
↑, upregulation; ↓, downregulation.

jdb-12-00024-t002_Table 2 Table 2 Metastatic lung cancer related to the NR2F family.

Primary Cancer Types	Genes	Inhibition/Promotion Metastasis	Models/Cell Lines/Tissues	Related Genes	Related Pathways	Reference	
Breast cancer	NR2F1-AS1↑	Inhibition	BALB/c nude mice and NOD/SCID mice; CA1h-P1, CA1h-P2 and 4175-LM2 cells	PTBP and miR-205	NR2F1/ΔNp63 axis	[66]	
Pancreatic cancer	NR2F1-AS1↑	Promotion	PC and matched paracancerous tissue samples; BxPC-3, Capan-2, CFPAC-1, SW1990, MIA PaCa-2, PANC-1 and HPDE cells; nude mouse	NR2F1	HIF pathway, AKT/mTOR pathway	[69]	
SACC	NR2F1↑	Inhibition	SACC patients specimens; SACC-83 and SACC-LM cells; nude mice	-	CXCL12/ CXCR4 pathway	[67]	
HNSCC	NR2F1↑	Inhibition	T-HEp3 cells and D-HEp3 cells; chicken chorioallantoic membrane (CAM) model; NU/J female mice model	-	TGF-β/SMAD4 signaling pathway	[65]	
Gastric cancer	Nr2f2↓	Inhibition	Gastric cancer patients specimens; SGC-7901, BGC-823, MGC-803, MKN-45, MKN-28 and AGS cell lines; nude mice	Fbxo21 and Zeb1	Nr2f2/Snail pathway	[68]	
Breast carcinoma	Nr2f2↓	Inhibition	ROSA26CRE-ERT2/+; Nr2f2flox/floxmouse model and PyMT+/−/ROSA26CRE-ERT2/+; Nr2f2flox/flox mouse model; B16F10 and LLC cells	Ang-1	VEGF signaling pathway	[24]	
↑, upregulation; ↓, downregulation.

Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.
==== Refs
References

1. Sever R. Glass C.K. Signaling by nuclear receptors Cold Spring Harb. Perspect. Biol. 2013 5 a016709 10.1101/cshperspect.a016709 23457262
2. Parris T.Z. Pan-cancer analyses of human nuclear receptors reveal transcriptome diversity and prognostic value across cancer types Sci. Rep. 2020 10 1873 10.1038/s41598-020-58842-6 32024906
3. Guzman A. Hughes C.H.K. Murphy B.D. Orphan nuclear receptors in angiogenesis and follicular development Reproduction 2021 162 R35 R54 10.1530/REP-21-0118 34270446
4. Wang L.H. Tsai S.Y. Sagami I. Tsai M.J. O’Malley B.W. Purification and characterization of chicken ovalbumin upstream promoter transcription factor from HeLa cells J. Biol. Chem. 1987 262 16080 16086 10.1016/S0021-9258(18)47698-3 3680243
5. Wang L.H. Ing N.H. Tsai S.Y. O’Malley B.W. Tsai M.J. The COUP-TFs compose a family of functionally related transcription factors Gene Expr. 1991 1 207 216 1820218
6. Barnhart K.M. Mellon P.L. The sequence of a murine cDNA encoding Ear-2, a nuclear orphan receptor Gene 1994 142 313 314 10.1016/0378-1119(94)90283-6 8194772
7. Park J.I. Tsai S.Y. Tsai M.J. Molecular mechanism of chicken ovalbumin upstream promoter-transcription factor (COUP-TF) actions Keio J. Med. 2003 52 174 181 10.2302/kjm.52.174 14529150
8. Leng X. Cooney A.J. Tsai S.Y. Tsai M.J. Molecular mechanisms of COUP-TF-mediated transcriptional repression: Evidence for transrepression and active repression Mol. Cell Biol. 1996 16 2332 2340 10.1128/MCB.16.5.2332 8628300
9. Tang K. Tsai S.Y. Tsai M.J. COUP-TFs and eye development Biochim. Biophys. Acta 2015 1849 201 209 10.1016/j.bbagrm.2014.05.022 24878540
10. Cooney A.J. Tsai S.Y. O’Malley B.W. Tsai M.J. Chicken ovalbumin upstream promoter transcription factor (COUP-TF) dimers bind to different GGTCA response elements, allowing COUP-TF to repress hormonal induction of the vitamin D3, thyroid hormone, and retinoic acid receptors Mol. Cell Biol. 1992 12 4153 4163 10.1128/mcb.12.9.4153-4163.1992 1324415
11. Kruse S.W. Suino-Powell K. Zhou X.E. Kretschman J.E. Reynolds R. Vonrhein C. Xu Y. Wang L. Tsai S.Y. Tsai M.J. Identification of COUP-TFII orphan nuclear receptor as a retinoic acid-activated receptor PLoS Biol. 2008 6 e227 10.1371/journal.pbio.0060227 18798693
12. Armentano M. Chou S.J. Tomassy G.S. Leingartner A. O’Leary D.D. Studer M. COUP-TFI regulates the balance of cortical patterning between frontal/motor and sensory areas Nat. Neurosci. 2007 10 1277 1286 10.1038/nn1958 17828260
13. Lodato S. Tomassy G.S. De Leonibus E. Uzcategui Y.G. Andolfi G. Armentano M. Touzot A. Gaztelu J.M. Arlotta P. Menendez de la Prida L. Loss of COUP-TFI alters the balance between caudal ganglionic eminence- and medial ganglionic eminence-derived cortical interneurons and results in resistance to epilepsy J. Neurosci. 2011 31 4650 4662 10.1523/JNEUROSCI.6580-10.2011 21430164
14. Alzu’bi A. Lindsay S.J. Harkin L.F. McIntyre J. Lisgo S.N. Clowry G.J. The Transcription Factors COUP-TFI and COUP-TFII have Distinct Roles in Arealisation and GABAergic Interneuron Specification in the Early Human Fetal Telencephalon Cereb. Cortex 2017 27 4971 4987 10.1093/cercor/bhx185 28922831
15. Yang X. Wan R. Liu Z. Feng S. Yang J. Jing N. Tang K. The differentiation and integration of the hippocampal dorsoventral axis are controlled by two nuclear receptor genes eLife 2023 12 RP86940 10.7554/eLife.86940.3 37751231
16. Bosch D.G. Boonstra F.N. Gonzaga-Jauregui C. Xu M. de Ligt J. Jhangiani S. Wiszniewski W. Muzny D.M. Yntema H.G. Pfundt R. NR2F1 mutations cause optic atrophy with intellectual disability Am. J. Hum. Genet. 2014 94 303 309 10.1016/j.ajhg.2014.01.002 24462372
17. Yang X. Feng S. Tang K. COUP-TF Genes, Human Diseases, and the Development of the Central Nervous System in Murine Models Curr. Top. Dev. Biol. 2017 125 275 301 10.1016/bs.ctdb.2016.12.002 28527575
18. Zhang K. Yu F. Zhu J. Han S. Chen J. Wu X. Chen Y. Shen T. Liao J. Guo W. Imbalance of Excitatory/Inhibitory Neuron Differentiation in Neurodevelopmental Disorders with an NR2F1 Point Mutation Cell Rep. 2020 31 107521 10.1016/j.celrep.2020.03.085 32320667
19. Yu C.T. Tang K. Suh J.M. Jiang R. Tsai S.Y. Tsai M.J. COUP-TFII is essential for metanephric mesenchyme formation and kidney precursor cell survival Development 2012 139 2330 2339 10.1242/dev.076299 22669823
20. Takamoto N. You L.R. Moses K. Chiang C. Zimmer W.E. Schwartz R.J. DeMayo F.J. Tsai M.J. Tsai S.Y. COUP-TFII is essential for radial and anteroposterior patterning of the stomach Development 2005 132 2179 2189 10.1242/dev.01808 15829524
21. You L.R. Takamoto N. Yu C.T. Tanaka T. Kodama T. Demayo F.J. Tsai S.Y. Tsai M.J. Mouse lacking COUP-TFII as an animal model of Bochdalek-type congenital diaphragmatic hernia Proc. Natl. Acad. Sci. USA 2005 102 16351 16356 10.1073/pnas.0507832102 16251273
22. Pelaez-Garcia A. Barderas R. Batlle R. Vinas-Castells R. Bartolome R.A. Torres S. Mendes M. Lopez-Lucendo M. Mazzolini R. Bonilla F. A proteomic analysis reveals that Snail regulates the expression of the nuclear orphan receptor Nuclear Receptor Subfamily 2 Group F Member 6 (Nr2f6) and interleukin 17 (IL-17) to inhibit adipocyte differentiation Mol. Cell Proteom. 2015 14 303 315 10.1074/mcp.M114.045328 25505127
23. Klepsch V. Hermann-Kleiter N. Do-Dinh P. Jakic B. Offermann A. Efremova M. Sopper S. Rieder D. Krogsdam A. Gamerith G. Nuclear receptor NR2F6 inhibition potentiates responses to PD-L1/PD-1 cancer immune checkpoint blockade Nat. Commun. 2018 9 1538 10.1038/s41467-018-04004-2 29670099
24. Qin J. Chen X. Xie X. Tsai M.J. Tsai S.Y. COUP-TFII regulates tumor growth and metastasis by modulating tumor angiogenesis Proc. Natl. Acad. Sci. USA 2010 107 3687 3692 10.1073/pnas.0914619107 20133706
25. Qin J. Wu S.P. Creighton C.J. Dai F. Xie X. Cheng C.M. Frolov A. Ayala G. Lin X. Feng X.H. COUP-TFII inhibits TGF-beta-induced growth barrier to promote prostate tumorigenesis Nature 2013 493 236 240 10.1038/nature11674 23201680
26. Wang L. Long H. Zheng Q. Bo X. Xiao X. Li B. Circular RNA circRHOT1 promotes hepatocellular carcinoma progression by initiation of NR2F6 expression Mol. Cancer 2019 18 119 10.1186/s12943-019-1046-7 31324186
27. Xu M. Qin J. Tsai S.Y. Tsai M.J. The role of the orphan nuclear receptor COUP-TFII in tumorigenesis Acta Pharmacol. Sin. 2015 36 32 36 10.1038/aps.2014.86 25283503
28. Sajinovic T. Baier G. New Insights into the Diverse Functions of the NR2F Nuclear Orphan Receptor Family Front. Biosci. 2023 28 13 10.31083/j.fbl2801013
29. Zhang Y. Zheng A. Xu R. Zhou F. Hao A. Yang H. Yang P. NR2F1-induced NR2F1-AS1 promotes esophageal squamous cell carcinoma progression via activating Hedgehog signaling pathway Biochem. Biophys. Res. Commun. 2019 519 497 504 10.1016/j.bbrc.2019.09.015 31530388
30. Bertacchi M. Parisot J. Studer M. The pleiotropic transcriptional regulator COUP-TFI plays multiple roles in neural development and disease Brain Res. 2019 1705 75 94 10.1016/j.brainres.2018.04.024 29709504
31. Herriges M. Morrisey E.E. Lung development: Orchestrating the generation and regeneration of a complex organ Development 2014 141 502 513 10.1242/dev.098186 24449833
32. Bellusci S. Grindley J. Emoto H. Itoh N. Hogan B.L. Fibroblast growth factor 10 (FGF10) and branching morphogenesis in the embryonic mouse lung Development 1997 124 4867 4878 10.1242/dev.124.23.4867 9428423
33. Park W.Y. Miranda B. Lebeche D. Hashimoto G. Cardoso W.V. FGF-10 is a chemotactic factor for distal epithelial buds during lung development Dev. Biol. 1998 201 125 134 10.1006/dbio.1998.8994 9740653
34. Weaver M. Dunn N.R. Hogan B.L. Bmp4 and Fgf10 play opposing roles during lung bud morphogenesis Development 2000 127 2695 2704 10.1242/dev.127.12.2695 10821767
35. Que J. Luo X. Schwartz R.J. Hogan B.L. Multiple roles for Sox2 in the developing and adult mouse trachea Development 2009 136 1899 1907 10.1242/dev.034629 19403656
36. Tompkins D.H. Besnard V. Lange A.W. Keiser A.R. Wert S.E. Bruno M.D. Whitsett J.A. Sox2 activates cell proliferation and differentiation in the respiratory epithelium Am. J. Respir. Cell Mol. Biol. 2011 45 101 110 10.1165/rcmb.2010-0149OC 20855650
37. Schittny J.C. Development of the lung Cell Tissue Res. 2017 367 427 444 10.1007/s00441-016-2545-0 28144783
38. Kimura Y. Suzuki T. Kaneko C. Darnel A.D. Moriya T. Suzuki S. Handa M. Ebina M. Nukiwa T. Sasano H. Retinoid receptors in the developing human lung Clin. Sci. 2002 103 613 621 10.1042/cs1030613 12444914
39. Miao Y. Tan C. Pek N.M. Yu Z. Iwasawa K. Kechele D.O. Sundaram N. Pastrana-Gomez V. Kishimoto K. Yang M.C. Deciphering Endothelial and Mesenchymal Organ Specification in Vascularized Lung and Intestinal Organoids bioRxiv 2024 10.1101/2024.02.06.577460
40. Schupp J.C. Adams T.S. Cosme C. Jr. Raredon M.S.B. Yuan Y. Omote N. Poli S. Chioccioli M. Rose K.A. Manning E.P. Integrated Single-Cell Atlas of Endothelial Cells of the Human Lung Circulation 2021 144 286 302 10.1161/CIRCULATIONAHA.120.052318 34030460
41. Shimamura Y. Tanaka J. Kakiuchi M. Sarmah H. Miura A. Hwang Y. Sawada A. Ninish Z. Yamada K. Mori M. A developmental program that regulates mammalian organ size offsets evolutionary distance bioRxiv 2022 10.1101/2022.10.19.512107
42. Tran T.T.T. Hung J.J. PTEN decreases NR2F1 expression to inhibit ciliogenesis during EGFR(L858R)-induced lung cancer progression Cell Death Dis. 2024 15 225 10.1038/s41419-024-06610-z 38499532
43. Klaassens M. van Dooren M. Eussen H.J. Douben H. den Dekker A.T. Lee C. Donahoe P.K. Galjaard R.J. Goemaere N. de Krijger R.R. Congenital diaphragmatic hernia and chromosome 15q26: Determination of a candidate region by use of fluorescent in situ hybridization and array-based comparative genomic hybridization Am. J. Hum. Genet. 2005 76 877 882 10.1086/429842 15750894
44. Wang L. Li Z. Wan R. Pan X. Li B. Zhao H. Yang J. Zhao W. Wang S. Wang Q. Single-Cell RNA Sequencing Provides New Insights into Therapeutic Roles of Thyroid Hormone in Idiopathic Pulmonary Fibrosis Am. J. Respir. Cell Mol. Biol. 2023 69 456 469 10.1165/rcmb.2023-0080OC 37402274
45. Li L. Galichon P. Xiao X. Figueroa-Ramirez A.C. Tamayo D. Lee J.J.K. Kalocsay M. Gonzalez-Sanchez D. Chancay S. Bonventre J.V. Orphan nuclear receptor COUP-TFII drives the myofibroblast metabolic shift leading to fibrosis bioRxiv 2020 10.1101/2020.06.05.135889
46. Kim W. Giannikou K. Dreier J.R. Lee S. Tyburczy M.E. Silverman E.K. Radzikowska E. Wu S. Wu C.L. Henske E.P. A genome-wide association study implicates NR2F2 in lymphangioleiomyomatosis pathogenesis Eur. Respir. J. 2019 53 1900329 10.1183/13993003.00329-2019 31000673
47. Relli V. Trerotola M. Guerra E. Alberti S. Abandoning the Notion of Non-Small Cell Lung Cancer Trends Mol. Med. 2019 25 585 594 10.1016/j.molmed.2019.04.012 31155338
48. Alberti S. Nutini M. Herzenberg L.A. DNA methylation prevents the amplification of TROP1, a tumor-associated cell surface antigen gene Proc. Natl. Acad. Sci. USA 1994 91 5833 5837 10.1073/pnas.91.13.5833 8016075
49. Nasr A.F. Nutini M. Palombo B. Guerra E. Alberti S. Mutations of TP53 induce loss of DNA methylation and amplification of the TROP1 gene Oncogene 2003 22 1668 1677 10.1038/sj.onc.1206248 12642870
50. Sanchez-Danes A. Blanpain C. Deciphering the cells of origin of squamous cell carcinomas Nat. Rev. Cancer 2018 18 549 561 10.1038/s41568-018-0024-5 29849070
51. Kim E.J. Kim J.S. Lee S. Cheon I. Kim S.R. Ko Y.H. Kang K. Tan X. Kurie J.M. Ahn Y.H. ZEB1-regulated lnc-Nr2f1 promotes the migration and invasion of lung adenocarcinoma cells Cancer Lett. 2022 533 215601 10.1016/j.canlet.2022.215601 35176421
52. Navab R. Gonzalez-Santos J.M. Johnston M.R. Liu J. Brodt P. Tsao M.S. Hu J. Expression of chicken ovalbumin upstream promoter-transcription factor II enhances invasiveness of human lung carcinoma cells Cancer Res. 2004 64 5097 5105 10.1158/0008-5472.CAN-03-1185 15289311
53. Liu W. Zhou Y. Duan W. Song J. Wei S. Xia S. Wang Y. Du X. Li E. Ren C. Glutathione peroxidase 4-dependent glutathione high-consumption drives acquired platinum chemoresistance in lung cancer-derived brain metastasis Clin. Transl. Med. 2021 11 e517 10.1002/ctm2.517 34586745
54. Jin C. Xiao L. Zhou Z. Zhu Y. Tian G. Ren S. MiR-142-3p suppresses the proliferation, migration and invasion through inhibition of NR2F6 in lung adenocarcinoma Hum. Cell 2019 32 437 446 10.1007/s13577-019-00258-0 31168689
55. Yoo S.S. Hong M.J. Lee J.H. Choi J.E. Lee S.Y. Lee J. Cha S.I. Kim C.H. Seok Y. Lee E. Association between polymorphisms in microRNA target sites and survival in early-stage non-small cell lung cancer Thorac. Cancer 2017 8 682 686 10.1111/1759-7714.12478 28922562
56. Klepsch V. Siegmund K. Baier G. Emerging Next-Generation Target for Cancer Immunotherapy Research: The Orphan Nuclear Receptor NR2F6 Cancers 2021 13 2600 10.3390/cancers13112600 34073258
57. Doi T. Sugimoto K. Puri P. Prenatal retinoic acid up-regulates pulmonary gene expression of COUP-TFII, FOG2, and GATA4 in pulmonary hypoplasia J. Pediatr. Surg. 2009 44 1933 1937 10.1016/j.jpedsurg.2009.04.027 19853750
58. Zhang C. Wu S. Song R. Liu C. Long noncoding RNA NR2F1-AS1 promotes the malignancy of non-small cell lung cancer via sponging microRNA-493-5p and thereby increasing ITGB1 expression Aging 2020 13 7660 7675 10.18632/aging.103564 32784268
59. Jin L. Chen C. Huang L. Sun Q. Bu L. Long noncoding RNA NR2F1-AS1 stimulates the tumorigenic behavior of non-small cell lung cancer cells by sponging miR-363-3p to increase SOX4 Open Med. 2022 17 87 95 10.1515/med-2021-0403
60. Jassim A. Rahrmann E.P. Simons B.D. Gilbertson R.J. Cancers make their own luck: Theories of cancer origins Nat. Rev. Cancer 2023 23 710 724 10.1038/s41568-023-00602-5 37488363
61. Fares J. Fares M.Y. Khachfe H.H. Salhab H.A. Fares Y. Molecular principles of metastasis: A hallmark of cancer revisited Signal Transduct. Target. Ther. 2020 5 28 10.1038/s41392-020-0134-x 32296047
62. Chaffer C.L. Weinberg R.A. A perspective on cancer cell metastasis Science 2011 331 1559 1564 10.1126/science.1203543 21436443
63. Altorki N.K. Markowitz G.J. Gao D. Port J.L. Saxena A. Stiles B. McGraw T. Mittal V. The lung microenvironment: An important regulator of tumour growth and metastasis Nat. Rev. Cancer 2019 19 9 31 10.1038/s41568-018-0081-9 30532012
64. Giancotti F.G. Mechanisms governing metastatic dormancy and reactivation Cell 2013 155 750 764 10.1016/j.cell.2013.10.029 24209616
65. Singh D.K. Carcamo S. Farias E.F. Hasson D. Zheng W. Sun D. Huang X. Cheung J. Nobre A.R. Kale N. 5-Azacytidine- and retinoic-acid-induced reprogramming of DCCs into dormancy suppresses metastasis via restored TGF-beta-SMAD4 signaling Cell Rep. 2023 42 112560 10.1016/j.celrep.2023.112560 37267946
66. Liu Y. Zhang P. Wu Q. Fang H. Wang Y. Xiao Y. Cong M. Wang T. He Y. Ma C. Long non-coding RNA NR2F1-AS1 induces breast cancer lung metastatic dormancy by regulating NR2F1 and DeltaNp63 Nat. Commun. 2021 12 5232 10.1038/s41467-021-25552-0 34475402
67. Gao X.L. Zheng M. Wang H.F. Dai L.L. Yu X.H. Yang X. Pang X. Li L. Zhang M. Wang S.S. NR2F1 contributes to cancer cell dormancy, invasion and metastasis of salivary adenoid cystic carcinoma by activating CXCL12/CXCR4 pathway BMC Cancer 2019 19 743 10.1186/s12885-019-5925-5 31357956
68. Jiang Y. Liu X. Shen R. Gu X. Qian W. Fbxo21 regulates the epithelial-to-mesenchymal transition through ubiquitination of Nr2f2 in gastric cancer J. Cancer 2021 12 1421 1430 10.7150/jca.49674 33531987
69. Liu Y. Chen S. Cai K. Zheng D. Zhu C. Li L. Wang F. He Z. Yu C. Sun C. Hypoxia-induced long noncoding RNA NR2F1-AS1 maintains pancreatic cancer proliferation, migration, and invasion by activating the NR2F1/AKT/mTOR axis Cell Death Dis. 2022 13 232 10.1038/s41419-022-04669-0 35283481
70. Weikum E.R. Liu X. Ortlund E.A. The nuclear receptor superfamily: A structural perspective Protein Sci. 2018 27 1876 1892 10.1002/pro.3496 30109749
71. Gangwar S.K. Kumar A. Yap K.C. Jose S. Parama D. Sethi G. Kumar A.P. Kunnumakkara A.B. Targeting Nuclear Receptors in Lung Cancer-Novel Therapeutic Prospects Pharmaceuticals 2022 15 624 10.3390/ph15050624 35631448
72. Jeong Y. Xie Y. Xiao G. Behrens C. Girard L. Wistuba I.I. Minna J.D. Mangelsdorf D.J. Nuclear receptor expression defines a set of prognostic biomarkers for lung cancer PLoS Med. 2010 7 e1000378 10.1371/journal.pmed.1000378 21179495
73. More E. Fellner T. Doppelmayr H. Hauser-Kronberger C. Dandachi N. Obrist P. Sandhofer F. Paulweber B. Activation of the MAP kinase pathway induces chicken ovalbumin upstream promoter-transcription factor II (COUP-TFII) expression in human breast cancer cell lines J. Endocrinol. 2003 176 83 94 10.1677/joe.0.1760083 12525252
74. Metivier R. Gay F.A. Hubner M.R. Flouriot G. Salbert G. Gannon F. Kah O. Pakdel F. Formation of an hER alpha-COUP-TFI complex enhances hER alpha AF-1 through Ser118 phosphorylation by MAPK EMBO J. 2002 21 3443 3453 10.1093/emboj/cdf344 12093745
75. Kaiser U. Hofmann J. Schilli M. Wegmann B. Klotz U. Wedel S. Virmani A.K. Wollmer E. Branscheid D. Gazdar A.F. Steroid-hormone receptors in cell lines and tumor biopsies of human lung cancer Int. J. Cancer 1996 67 357 364 10.1002/(SICI)1097-0215(19960729)67:3<357::AID-IJC9>3.0.CO;2-Q 8707409
76. Canver C.C. Memoli V.A. Vanderveer P.L. Dingivan C.A. Mentzer R.M. Jr. Sex hormone receptors in non-small-cell lung cancer in human beings J. Thorac. Cardiovasc. Surg. 1994 108 153 157 10.1016/S0022-5223(94)70232-2 8028359
77. Yang M.H. Estrogen receptor in female lung carcinoma Zhonghua Jie He He Hu Xi Za Zhi 1992 15 138 189 138–140+189 1335368
78. Chen X.Q. Zheng L.X. Li Z.Y. Lin T.Y. Clinicopathological significance of oestrogen receptor expression in non-small cell lung cancer J. Int. Med. Res. 2017 45 51 58 10.1177/0300060516666229 27913747
79. Huang Q. Zhang Z. Liao Y. Liu C. Fan S. Wei X. Ai B. Xiong J. 17beta-estradiol upregulates IL6 expression through the ERbeta pathway to promote lung adenocarcinoma progression J. Exp. Clin. Cancer Res. 2018 37 133 10.1186/s13046-018-0804-5 29970138
80. Tsai S.Y. Carlstedt-Duke J. Weigel N.L. Dahlman K. Gustafsson J.A. Tsai M.J. O’Malley B.W. Molecular interactions of steroid hormone receptor with its enhancer element: Evidence for receptor dimer formation Cell 1988 55 361 369 10.1016/0092-8674(88)90059-1 3167984
81. Sanchez Calle A. Yamamoto T. Kawamura Y. Hironaka-Mitsuhashi A. Ono M. Tsuda H. Shimomura A. Tamura K. Takeshita F. Ochiya T. Long non-coding NR2F1-AS1 is associated with tumor recurrence in estrogen receptor-positive breast cancers Mol. Oncol. 2020 14 2271 2287 10.1002/1878-0261.12704 32392629
82. Wetendorf M. DeMayo F.J. Progesterone receptor signaling in the initiation of pregnancy and preservation of a healthy uterus Int. J. Dev. Biol. 2014 58 95 106 10.1387/ijdb.140069mw 25023675
83. Stabile L.P. Dacic S. Land S.R. Lenzner D.E. Dhir R. Acquafondata M. Landreneau R.J. Grandis J.R. Siegfried J.M. Combined analysis of estrogen receptor beta-1 and progesterone receptor expression identifies lung cancer patients with poor outcome Clin. Cancer Res. 2011 17 154 164 10.1158/1078-0432.CCR-10-0992 21062926
84. Mattern J. Klinga K. Runnebaum B. Volm M. Influence of hormone therapy on human lung tumors transplanted into nude mice Oncology 1985 42 388 390 10.1159/000226069 4069553
85. Laursen K.B. Mongan N.P. Zhuang Y. Ng M.M. Benoit Y.D. Gudas L.J. Polycomb recruitment attenuates retinoic acid-induced transcription of the bivalent NR2F1 gene Nucleic Acids Res. 2013 41 6430 6443 10.1093/nar/gkt367 23666625
86. Lin B. Chen G.Q. Xiao D. Kolluri S.K. Cao X. Su H. Zhang X.K. Orphan receptor COUP-TF is required for induction of retinoic acid receptor beta, growth inhibition, and apoptosis by retinoic acid in cancer cells Mol. Cell Biol. 2000 20 957 970 10.1128/MCB.20.3.957-970.2000 10629053
87. Bushue N. Wan Y.J. Retinoid pathway and cancer therapeutics Adv. Drug Deliv. Rev. 2010 62 1285 1298 10.1016/j.addr.2010.07.003 20654663
88. Tang X.H. Gudas L.J. Retinoids, retinoic acid receptors, and cancer Annu. Rev. Pathol. 2011 6 345 364 10.1146/annurev-pathol-011110-130303 21073338
89. Gebert J.F. Moghal N. Frangioni J.V. Sugarbaker D.J. Neel B.G. High frequency of retinoic acid receptor beta abnormalities in human lung cancer Oncogene 1991 6 1859 1868 1717924
90. Houle B. Rochette-Egly C. Bradley W.E. Tumor-suppressive effect of the retinoic acid receptor beta in human epidermoid lung cancer cells Proc. Natl. Acad. Sci. USA 1993 90 985 989 10.1073/pnas.90.3.985 8381540
91. Xu X.C. Sozzi G. Lee J.S. Lee J.J. Pastorino U. Pilotti S. Kurie J.M. Hong W.K. Lotan R. Suppression of retinoic acid receptor beta in non-small-cell lung cancer in vivo: Implications for lung cancer development J. Natl. Cancer Inst. 1997 89 624 629 10.1093/jnci/89.9.624 9150186
92. Chang Y.S. Chung J.H. Shin D.H. Chung K.Y. Kim Y.S. Chang J. Kim S.K. Kim S.K. Retinoic acid receptor-beta expression in stage I non-small cell lung cancer and adjacent normal appearing bronchial epithelium Yonsei Med. J. 2004 45 435 442 10.3349/ymj.2004.45.3.435 15227730
93. Germain P. Chambon P. Eichele G. Evans R.M. Lazar M.A. Leid M. De Lera A.R. Lotan R. Mangelsdorf D.J. Gronemeyer H. International Union of Pharmacology. LXIII. Retinoid X receptors Pharmacol. Rev. 2006 58 760 772 10.1124/pr.58.4.7 17132853
94. Mangelsdorf D.J. Evans R.M. The RXR heterodimers and orphan receptors Cell 1995 83 841 850 10.1016/0092-8674(95)90200-7 8521508
95. Kuznetsova E.S. Zinovieva O.L. Oparina N.Y. Prokofjeva M.M. Spirin P.V. Favorskaya I.A. Zborovskaya I.B. Lisitsyn N.A. Prassolov V.S. Mashkova T.D. Abnormal expression of genes that regulate retinoid metabolism and signaling in non-small-cell lung cancer Mol. Biol. 2016 50 255 265 10.1134/S0026893316020138
96. Ai X. Mao F. Shen S. Shentu Y. Wang J. Lu S. Bexarotene inhibits the viability of non-small cell lung cancer cells via slc10a2/PPARgamma/PTEN/mTOR signaling pathway BMC Cancer 2018 18 407 10.1186/s12885-018-4224-x 29642873
97. Okamura M. Kudo H. Wakabayashi K. Tanaka T. Nonaka A. Uchida A. Tsutsumi S. Sakakibara I. Naito M. Osborne T.F. COUP-TFII acts downstream of Wnt/beta-catenin signal to silence PPARgamma gene expression and repress adipogenesis Proc. Natl. Acad. Sci. USA 2009 106 5819 5824 10.1073/pnas.0901676106 19307559
98. Sasaki H. Tanahashi M. Yukiue H. Moiriyama S. Kobayashi Y. Nakashima Y. Kaji M. Kiriyama M. Fukai I. Yamakawa Y. Decreased perioxisome proliferator-activated receptor gamma gene expression was correlated with poor prognosis in patients with lung cancer Lung Cancer 2002 36 71 76 10.1016/S0169-5002(01)00449-4 11891036
99. Keshamouni V.G. Reddy R.C. Arenberg D.A. Joel B. Thannickal V.J. Kalemkerian G.P. Standiford T.J. Peroxisome proliferator-activated receptor-gamma activation inhibits tumor progression in non-small-cell lung cancer Oncogene 2004 23 100 108 10.1038/sj.onc.1206885 14712215
100. Sandgren M. Danforth L. Plasse T.F. DeLuca H.F. 1,25-Dihydroxyvitamin D3 receptors in human carcinomas: A pilot study Cancer Res. 1991 51 2021 2024 1849039
101. Srinivasan M. Parwani A.V. Hershberger P.A. Lenzner D.E. Weissfeld J.L. Nuclear vitamin D receptor expression is associated with improved survival in non-small cell lung cancer J. Steroid Biochem. Mol. Biol. 2011 123 30 36 10.1016/j.jsbmb.2010.10.002 20955794
102. Mohamed F. Abdelaziz A.O. Kasem A.H. Ellethy T. Gayyed M.F. Thyroid hormone receptor alpha1 acts as a new squamous cell lung cancer diagnostic marker and poor prognosis predictor Sci. Rep. 2021 11 7944 10.1038/s41598-021-86754-6 33846395
103. Iwasaki Y. Sunaga N. Tomizawa Y. Imai H. Iijima H. Yanagitani N. Horiguchi K. Yamada M. Mori M. Epigenetic inactivation of the thyroid hormone receptor beta1 gene at 3p24.2 in lung cancer Ann. Surg. Oncol. 2010 17 2222 2228 10.1245/s10434-010-0956-9 20155399
104. Kwon M.C. Berns A. Mouse models for lung cancer Mol. Oncol. 2013 7 165 177 10.1016/j.molonc.2013.02.010 23481268
105. Yang Z. Gimple R.C. Zhou N. Zhao L. Gustafsson J.A. Zhou S. Targeting Nuclear Receptors for Cancer Therapy: Premises, Promises, and Challenges Trends Cancer 2021 7 541 556 10.1016/j.trecan.2020.11.007 33341430
106. Maniatis S. Petrescu J. Phatnani H. Spatially resolved transcriptomics and its applications in cancer Curr. Opin. Genet. Dev. 2021 66 70 77 10.1016/j.gde.2020.12.002 33434721
107. Zhang Q. Abdo R. Iosef C. Kaneko T. Cecchini M. Han V.K. Li S.S. The spatial transcriptomic landscape of non-small cell lung cancer brain metastasis Nat. Commun. 2022 13 5983 10.1038/s41467-022-33365-y 36216799
